GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
Issued: London UK
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
Full details of GSK's results for the first quarter of 2011 can be found in the investors section of GSK.com.
GlaxoSmithKline enquiries: |
|
|
|
UK Media enquiries: |
David Mawdsley |
(020) 8047 5502 |
|
|
Claire Brough |
(020) 8047 5502 |
|
|
Stephen Rea |
(020) 8047 5502 |
|
|
Alexandra Harrison |
(020) 8047 5502 |
|
Janet Morgan |
(020) 8047 5502 |
|
|
David Daley |
(020) 8047 5502 |
|
|
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Jennifer Armstrong |
(919) 483 2839 |
|
|
||
|
European Analyst/Investor enquiries: |
Sally Ferguson |
(020) 8047 5543 |
|
Gary Davies |
(020) 8047 5503 |
|
|
Ziba Shamsi |
(020) 8047 3289 |
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jeff McLaughlin |
(215) 751 7002 |
